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ventilation, 2% (group I) vs. 9% (group II), p<0.01; preoperative inotropes,
11% (group I) vs. 37% (group II), p<0.01. Among the donors, age older than
60 years, 7% (group I) vs. 13% (group II), p=0.01, norepinephrine support at
retrieval, 74% (group I) vs. 88% (group II), p<0.01 and ischemic time,
156 min. (group I) vs. 183 min. (group II), p<0.01. Even if the occurrence of
primary graft dysfunction was the similar in both groups, 21% (group I) vs.
27% (group II), this complication was treated with high dose inotropes in 10%
(group I) vs. 2% (group II), p<0.01; with ECMO in 8% (group I) vs. 25%
(group II), p<0.01. One-year mortality and 5-years survival were similar in
both groups: 26% (group I) vs. 29% (group II), 67% (group I) vs. 62%
(group II).
Conclusion: The evolution of waiting list criteria and perioperative use of
ECMO allowed us to transplant sicker recipients, using marginal donors,
without any significant impact on short and mid-term survival.
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Background: Few data are available on the value of BNP in older-old sub-
jects. The aim of this study was to evaluate the benefit of BNP for heart
failure diagnosis in very old patients.
Methods: The BED is a French multicenter observational prospective
study that enrolled 383 very old subjects (≥80 yo) hospitalized in geriatric care
with acute dyspnea. BNP was measured in acute phase, before any diuretic
treatment. Cardiologists categorized the subjects into 3 subgroups according to
ESC criteria and blinded to BNP level: heart failure (HF), respiratory failure
and mixed disease (HF and respiratory failure combined). Subjects with mixed
disease were then reclassified into HF or respiratory failure groups according
to the predominant feature (cardiac or respiratory). We analyzed the prog-
nostic value (sensibility, sensitivity and area under curve (AUC)) of the BNP
for the diagnosis of HF, mixed disease included and excluded.
Results: Mean age was 89±5 years, 66% of the patients were women, 57%
had previous history of HF, 67% hypertension, 13% diabetes, 33% coronary
heart disease and 49% atrial fibrillation. Mean LVEF was 56±13%. Several
patients had non-cardiac comorbidities, malnutrition 48%, severe renal failure
41%, dementia 38%, depression 32%, COPD 17%, and cancer 12%. Fifty per-
cent of the subjects had cardiac dyspnea, 26% respiratory dyspnea and 24%
dyspnea of mixed origin. Mean BNP values were 675 (835), 301 (366), 558
(796) pg/mL (p<0.001) in cardiac dyspnea, respiratory dyspnea and mixed
origin subjects respectively. However, the AUC was only 0.68 and 0.67 with
mixed dyspnea included and excluded respectively. In the overall population,
the sensitivity and specificity was 86% and 33% for a cutoff of 100 pg/mL,
48% and 73% for a cutoff of 400 pg/mL and 26% and 86% for a cutoff of
800 pg/mL. Similar results were obtained with mixed dyspnea subjects excluded.
Conclusion: In very old patients, BNP has a poor sensitivity and speci-
ficity for discriminating cardiac from pulmonary dyspnea.
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Introduction: Heart failure with preserved ejection fraction (HFPEF) is
an incurable but prevalent disease associated with poor prognosis. Whether
cardiac MRI with late enhancement (LE) analysis could provide new
insight into myocardial structure and pathophysiology is investigated in this
work.
Methods: 50 consecutive and clinically stabilized patients with HFPEF
(Framingham clinical criteria, EF >50% and BNP level >100 pg/ml) were
explored by MRI (Siemens 1.5T, Symphony and Avanto) for cine-SSFP as
well as 10-min LE following Gadolinium infusion sequences, 2 months after
an acute decompensation. Patients were stratified according to the distribution
of LE imaging at least in 2 adjacent segments (subendocardial, subepicardial
or intramyocardial). Interestingly subendocardial LE localization was consid-
ered as a marker of myocardial infarction. Demographic data and medical his-
tory were also collected.
Results: Mean age was 73±9 yrs and sex ratio was 0.85. The magnitude of
hypertension, diabetes and chronic kidney disease was 78%, 47% and 24%,
respectively. A history of ischemic heart disease (prior MI and/or isolated cor-
onary lesions) was reported in 23% of pts. By MRI, EF was 57±11%, indexed
left ventricular end-diastolic volume was 78±23 ml/m² and left atrial end-
systolic volume was 111±35 ml. Late enhancement analysis was completed in
47 patients. Twenty two patients had no LE. Among the 25 remaining patients,
subendocardial, intramyocardial and subepicardial LE was found in 62%, 32%
and 20% of cases, respectively. The diagnosis of myocardial infarction was
more frequently detected by MRI than orally reported in the medical report
(32% vs. 23% respectively, p<0,0001) overall.
Conclusion: Cardiac MRI provides new insight into HFPEF by revealing
more silent ischemic heart disease than orally documented
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Background: the prevalence of atrial arrhythmias (AAr) in patients with
heart failure (HF) is high, namely in HF with preserved ejection fraction
(HFpEF). KaRen study is a French and Swedish prospective registry enrolling
patients with an acute HFpEF and reassessing these patients 4-8 weeks later
after conventional HF treatment.
Aim: we sought to define the exact prevalence and the main clinical cor-
relates of AAr diagnosed in the patients included in KaRen.
Method: 535 patients were prospectively recruited and 58.5% had a his-
tory of AAr. Clinical characteristics, co-morbidities, risk factors, left ventric-
ular ejection fraction, blood chemistry and drug treatment were recorded at
baseline and 4-8 weeks later.
Results: The main characteristics at baseline and 4-8 weeks follow-up of
the 313 pts with a history of AAr (AAr+) and of the 220 without AAr (AAr-)
are displayed in the table. Patients with AAr were older (p=0.0004) and tend
to have higher NT-proBNP levels at baseline. There were no significant dif-
ferences for diabetes, Serum creatinin, hemoglobin or left ventricular ejection
fraction. In the 313 patients AAr+, 69% were treated by beta-blockers at the
admission (significantly more than in group AAr-, p=0.0034), 59.7% were
treated with an ACE-inhibitor, 60% got an oral anticoagulant (p<0.0001) at
baseline and 73% at the 4-8week visit.
Conclusion: AAr are extremely prevalent in patient admitted for HFpEF.
Prevalence increases with increasing age and higher blood pressure. It leads to
significantly more prescription of beta-blockers. Interestinglly, NT-proBNP
decreased more in AAr+ patients after treatment.
